Partial
Partially Aligned
Patient Risk:
Medium
Summary
Partially aligned: hypertension indication and general beta-blocker mechanism elements are supported. However, several claims are not supported by the provided label excerpts (e.g., coronary heart disease, heart failure use to reduce hospitalization/death, tablet strength range, and brand/manufacturer availability).
Category Scores
Accurate Statements
Bisoprolol fumarate is a beta-blocker.
SECTION 12 and label characterization as a beta1-selective adrenoceptor blocking agent.
Bisoprolol fumarate 5 mg is used to treat high blood pressure (hypertension).
SECTION 1: Indicated in management of hypertension.
The appropriate bisoprolol fumarate dosage is determined by a healthcare provider based on the patient's condition and response to treatment.
SECTION 2: “The dose … must be individualized to the needs of the patient.”
The dose of bisoprolol fumarate can start at 5 mg once daily, and may be adjusted based on antihypertensive effect.
SECTION 2: usual starting dose 5 mg once daily; may be increased to 10 mg then 20 mg if inadequate.
Bisoprolol fumarate is available in tablet strengths including 2.5 mg, 5 mg, and 10 mg.
SECTION 2: discusses starting dose options of 2.5 mg and 5 mg and titration to 10 mg (and further to 20 mg if needed).
Unsupported Statements
Bisoprolol fumarate 5 mg is used to treat coronary heart disease.
No coronary heart disease indication is present in the provided label excerpts (SECTION 1 only states hypertension).
Bisoprolol fumarate is prescribed for heart failure.
The provided excerpts include warnings about cardiac failure but do not provide an indication for heart failure in SECTION 1.
In patients with heart failure, bisoprolol fumarate is used to reduce the risk of hospitalization.
No heart failure indication or related outcome claims (hospitalization risk reduction) are present in the provided label excerpts.
In patients with heart failure, bisoprolol fumarate is used to reduce the risk of death.
No heart failure indication or related outcome claims (mortality risk reduction) are present in the provided label excerpts.
Bisoprolol fumarate works by slowing down the heart rate.
The provided excerpts mention heart rate effects in clinical study results (SECTION 14) but do not explicitly connect mechanism-of-action text in a way that supports a general mechanism statement.
Bisoprolol fumarate reduces the force with which the heart pumps blood.
The provided excerpts discuss myocardial contractility depression as a consequence of beta-blockade in the warnings section, but the response frames it as a general effect/mechanism; this is not stated explicitly as a general mechanism or primary labeled effect.
Slowing heart rate and reducing pumping force decreases blood pressure.
No label excerpt explicitly states this causal chain linking those effects to blood pressure reduction.
Bisoprolol fumarate helps the heart pump more efficiently over time.
No provided label excerpt states this as an effect in the context of treatment efficacy.
Bisoprolol fumarate is manufactured by several pharmaceutical companies.
No label excerpt provided supports manufacturing by multiple companies.
Brand names of bisoprolol fumarate include Zebeta and Concor.
No label excerpt provided supports specific brand names.
Generic versions of bisoprolol fumarate are widely available.
No label excerpt provided supports availability of generics or the breadth of availability.
Contradictions
Important Omissions
If evaluating dosing adequacy/safety: label excerpts specify hepatic/renal impairment starting dose adjustment to 2.5 mg and caution/titration, and additional elderly/dialysis considerations; the response does not mention these.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported indication claims (coronary heart disease and heart failure risk-reduction endpoints) could mislead use outside the provided label indication (hypertension). Mechanism statements are partly unsupported. Dosing omissions for hepatic/renal impairment increase potential inaccuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported claims not present in the provided label excerpts (notably coronary heart disease and heart failure outcomes; brand/manufacturer/generic availability; and several mechanistic/causal statements).
Suggested Improvement
Limit indications to hypertension (Section 1). Remove or qualify unsupported heart failure/coronary heart disease and brand/generic availability statements. For mechanism/clinical effect, reference only what is explicitly supported by provided label text. Include key dosing considerations from Section 2 for hepatic/renal dysfunction if discussing dosage.